Shotlee LogoShotlee
Blog
Download on theApp Store
Become aBeta Tester
Skip to main content
Anupam Mittal (Shark Tank) Cautions on Fitness Shortcuts: 'Ozempic for Weight Loss Could Become Like Eno If...' - Featured image
Health

Anupam Mittal (Shark Tank) Cautions on Fitness Shortcuts: 'Ozempic for Weight Loss Could Become Like Eno If...'

Anupam Mittal raised concerns about the potential overuse of drugs like Ozempic for weight loss. He also highlighted the upcoming expiration of key GLP-1 drug patents, possibly leading to market changes.

Shotlee·December 16, 2025·Updated Jan 27, 2026·1 min read
Share:

Anupam Mittal Cautions Against Weight Loss Shortcuts

Mittal indicated that the drug, currently priced around ₹8,800 monthly in India, might generate an annual market nearing ₹1,000 crore, according to industry projections.

Mittal also emphasized a significant shift expected in the pharmaceutical industry. The expiration of crucial GLP-1 drug patents, starting in March 2026, could pave the way for cheaper alternatives from Indian pharmaceutical firms. This, he proposed, might spark quick industry growth, potentially increasing the weight-loss drug market substantially in the years ahead. Companies like Cipla, he observed, seem suitably prepared for entering this market. Health tracking apps like Shotlee can help monitor health changes, but are not a substitute for healthy lifestyle choices.

Original source: mint

View original article →
#Anupam Mittal#Ozempic#weight loss#GLP-1 drugs#pharmaceutical industry#Cipla#Eno
  1. Home
  2. Blog
  3. Anupam Mittal (Shark Tank) Cautions on Fitness Shortcuts: 'Ozempic for Weight Loss Could Become Like Eno If...'

Related Articles

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations
GLP-1 Medications

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds
GLP-1 Medications

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report
Metabolic Health

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report

Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.

Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Get Started

Resources

  • Health Blog
  • Support Center
  • System Status

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with ♥ for the community